AstraZeneca revenue breakdown by business segment: 34.9% from ONCOLOGY, 6.3% from OTHER MEDICINES, 10.7% from COVID-19, 21.4% from BIOPHARMACEUTICALS: CVRM, 16.1% from BIOPHARMACEUTICALS: R&I, 8.2% from RARE DISEASE and 2.3% from Other
USD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
---|---|---|---|---|
Revenue | 22.1b | 24.4b | 26.6b | 37.4b |
Cost of goods sold | (1.2b) | (1.2b) | (2.2b) | (5.9b) |
Gross profit | 21.7b | 23.7b | 25.0b | 33.0b |
R&D expense | (5.9b) | (6.1b) | (6.0b) | (9.7b) |
Operating expense total | (16.4b) | (18.2b) | (17.8b) | (25.9b) |
Depreciation and amortization | (3.8b) | (3.8b) | (3.1b) | (6.5b) |
EBITDA | 5.2b | 5.4b | 7.2b | 7.0b |
EBIT | 3.3b | 2.8b | 5.1b | 992.0m |
Interest expense | (1.4b) | (1.4b) | (1.3b) | (1.3b) |
Interest income | 138.0m | 22.0m | 36.0m | |
Pre tax profit | 2.0b | 1.5b | 3.9b | (265.0m) |
Income tax expense | 57.0m | (321.0m) | (772.0m) | 380.0m |
Net Income | 2.1b | 1.2b | 3.1b | 115.0m |
USD | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 |
---|---|---|---|---|---|---|---|---|---|
Revenue | 5.5b | 5.8b | 6.4b | 6.4b | 6.3b | 6.6b | 7.3b | 8.2b | 9.9b |
Cost of goods sold | (453.0m) | (336.0m) | (635.0m) | (579.0m) | (274.0m) | (569.0m) | (1.1b) | (1.4b) | (969.0m) |
Gross profit | 5.6b | 5.6b | 6.1b | 6.3b | 6.1b | 6.3b | 7.4b | 6.9b | 8.9b |
R&D expense | (1.3b) | (1.4b) | (1.3b) | (1.4b) | (1.4b) | (1.5b) | (1.7b) | (1.8b) | (3.6b) |
Operating expense total | (4.4b) | (3.9b) | (4.6b) | (4.6b) | (3.8b) | (4.9b) | (5.1b) | (4.7b) | (8.2b) |
Depreciation and amortization | (676.0m) | (727.0m) | (716.0m) | (841.0m) | (710.0m) | (801.0m) | (797.0m) | (753.0m) | (2.8b) |
EBITDA | 1.2b | 1.7b | 1.4b | 1.7b | 2.3b | 1.4b | 2.4b | 2.1b | 736.0m |
EBIT | 1.1b | 461.0m | 725.0m | 1.2b | 1.3b | 1.2b | 1.9b | 1.1b | (1.7b) |
Interest expense | (367.0m) | (361.0m) | (353.0m) | (332.0m) | (329.0m) | (324.0m) | (303.0m) | (326.0m) | (335.0m) |
Interest income | 55.0m | 41.0m | 37.0m | 51.0m | 22.0m | 7.0m | 20.0m | 7.0m | 15.0m |
Pre tax profit | 758.0m | 141.0m | 409.0m | 935.0m | 961.0m | 853.0m | 1.6b | 764.0m | (2.0b) |
Income tax expense | (195.0m) | (34.0m) | (129.0m) | (185.0m) | (223.0m) | (202.0m) | (46.0m) | (214.0m) | 350.0m |
Net Income | 563.0m | 107.0m | 280.0m | 750.0m | 738.0m | 651.0m | 1.6b | 550.0m | (1.7b) |
USD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
---|---|---|---|---|
Cash | 4.8b | 5.4b | 7.8b | 6.3b |
Accounts Receivable | 3.0b | 3.6b | 3.8b | 9.6b |
Prepaid Expenses | 1.6b | 1.2b | 2.1b | 663.0m |
Inventories | 2.9b | 3.2b | 4.0b | 9.0b |
Current Assets | 15.6b | 15.6b | 19.5b | 26.2b |
PP&E | 7.4b | 8.3b | 8.3b | 9.2b |
Goodwill | 11.7b | 11.7b | 11.8b | 20.0b |
Total Assets | 60.7b | 61.4b | 66.7b | 105.4b |
Accounts Payable | 1.7b | 1.8b | 2.4b | 18.9b |
Short-term debt | 1.8b | 2.0b | 2.3b | 1.9b |
Current Liabilities | 16.3b | 18.1b | 20.3b | 22.6b |
Long-term debt | 17.4b | 16.2b | 18.0b | 28.9b |
Non-Current Liabilities | 30.3b | 28.7b | 30.8b | 43.5b |
Total Debt | 19.1b | 18.2b | 20.3b | 30.8b |
Total Liabilities | 46.6b | 46.8b | 51.1b | 66.1b |
Common Stock | 317.0m | 328.0m | 328.0m | 387.0m |
Additional Paid-in Capital | 4.4b | 7.9b | 8.0b | 35.1b |
Retained Earnings | 5.7b | 2.8b | 5.3b | 1.7b |
Total Equity | 14.0b | 14.6b | 15.6b | 39.3b |
USD | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 |
---|---|---|---|---|---|---|---|---|---|
Cash | 4.1b | 5.4b | 4.0b | 3.4b | 5.7b | 8.1b | 7.6b | 15.6b | 7.1b |
Accounts Receivable | 5.3b | 5.3b | 5.3b | 5.1b | 5.0b | 5.7b | 6.3b | 6.4b | 8.3b |
Prepaid Expenses | 118.0m | 246.0m | 228.0m | 262.0m | 213.0m | 332.0m | 347.0m | 486.0m | 596.0m |
Inventories | 3.1b | 3.2b | 3.1b | 3.1b | 3.6b | 3.7b | 4.3b | 4.8b | 10.5b |
Current Assets | 13.6b | 15.2b | 13.5b | 12.8b | 14.9b | 18.2b | 18.7b | 27.3b | 26.7b |
PP&E | 7.4b | 7.4b | 8.0b | 7.3b | 7.5b | 7.7b | 8.2b | 8.4b | 9.2b |
Goodwill | 11.7b | 11.7b | 11.6b | 11.6b | 11.6b | 11.7b | 11.8b | 11.8b | 20.1b |
Total Assets | 61.1b | 61.9b | 58.9b | 57.2b | 59.9b | 64.1b | 64.9b | 73.6b | 107.2b |
Accounts Payable | 13.1b | 12.6b | 12.5b | 12.6b | 12.0b | 13.4b | 17.4b | 17.7b | 18.7b |
Short-term debt | 3.7b | 1.8b | 577.0m | 2.5b | 4.1b | 3.6b | 2.3b | 2.9b | 3.0b |
Current Liabilities | 18.3b | 16.0b | 14.8b | 17.0b | 18.2b | 18.9b | 21.5b | 22.2b | 23.6b |
Long-term debt | 17.9b | 17.9b | 17.6b | 16.1b | 15.6b | 18.8b | 17.9b | 24.6b | 28.9b |
Non-Current Liabilities | 30.8b | 30.8b | 30.5b | 28.0b | 28.1b | 31.6b | 29.0b | 35.7b | 43.7b |
Total Debt | 21.6b | 19.7b | 18.2b | 18.6b | 19.7b | 22.3b | 20.1b | 27.5b | 31.9b |
Total Liabilities | 49.0b | 46.8b | 45.2b | 45.0b | 46.3b | 50.5b | 50.5b | 57.9b | 67.3b |
Common Stock | 317.0m | 328.0m | 328.0m | 328.0m | 328.0m | 328.0m | 328.0m | 328.0m | 387.0m |
Additional Paid-in Capital | 4.4b | 7.9b | 7.9b | 7.9b | 8.0b | 8.0b | 8.0b | 8.0b | 35.1b |
Retained Earnings | 3.7b | 3.3b | 1.9b | 448.0m | 1.9b | 1.9b | 4.1b | 5.3b | 2.2b |
Total Equity | 12.0b | 15.1b | 13.7b | 12.2b | 13.7b | 13.6b | 14.4b | 15.7b | 39.9b |
USD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
---|---|---|---|---|
Net Income | 2.0b | 1.5b | 3.9b | (265.0m) |
Depreciation and Amortization | 3.8b | 3.8b | 3.1b | 6.5b |
Accounts Receivable | (523.0m) | (898.0m) | (739.0m) | |
Inventories | (13.0m) | (316.0m) | (621.0m) | |
Accounts Payable | (103.0m) | 868.0m | 1.7b | |
Cash From Operating Activities | 2.6b | 3.0b | 4.8b | 6.0b |
Cash From Investing Activities | 963.0m | (657.0m) | (285.0m) | (11.1b) |
Short-term Borrowings | (98.0m) | (516.0m) | 288.0m | (516.0m) |
Long-term Borrowings | 1.6b | (1.0b) | 1.4b | 8.2b |
Dividends Paid | (3.5b) | (3.6b) | (3.6b) | (3.9b) |
Cash From Financing Activities | (2.0b) | (1.8b) | (2.2b) | 3.6b |
Net Change in Cash | 1.5b | 552.0m | 2.3b | (1.5b) |
USD | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 |
---|---|---|---|---|---|---|---|---|---|
Net Income | 758.0m | 899.0m | 1.3b | 935.0m | 1.9b | 2.7b | 1.6b | 2.4b | 371.0m |
Depreciation and Amortization | 676.0m | 1.4b | 2.1b | 841.0m | 1.6b | 2.4b | 797.0m | 1.6b | 4.3b |
Cash From Operating Activities | (387.0m) | 491.0m | 1.6b | 139.0m | 1.2b | 3.0b | 1.9b | 2.8b | 4.5b |
Cash From Investing Activities | 328.0m | (789.0m) | (715.0m) | 9.0m | 157.0m | (423.0m) | 555.0m | 319.0m | (10.1b) |
Short-term Borrowings | 1.2b | (148.0m) | (686.0m) | 123.0m | 1.4b | 858.0m | (240.0m) | (182.0m) | (261.0m) |
Long-term Borrowings | 500.0m | (1.0b) | 3.0b | (4.0m) | 7.3b | 9.0b | |||
Dividends Paid | (2.4b) | (2.4b) | (3.6b) | (2.4b) | (2.5b) | (3.7b) | (2.5b) | (2.5b) | (3.9b) |
Cash From Financing Activities | (698.0m) | 941.0m | (1.8b) | (2.4b) | (1.2b) | 7.0m | (2.7b) | 4.6b | 4.7b |
Net Change in Cash | (745.0m) | 659.0m | (892.0m) | (2.2b) | 82.0m | 2.6b | (309.0m) | 7.7b | (973.0m) |
USD | FY, 2018 |
---|---|
EV/EBITDA | 21.5 x |
EV/EBIT | 33.8 x |
EV/CFO | 42.2 x |
Revenue/Employee | 342.0k |
FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q4, 2018 | FY, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q4, 2019 | FY, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q4, 2020 | FY, 2020 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Projects in R&D Pipeline | 99 | 133 | 146 | 132 | 144 | 149 | 167 | 171 | ||||||||||||
Phase I Trials Projects | 33 | 24 | 44 | 41 | 50 | 38 | 34 | 35 | ||||||||||||
Phase II Trials Projects | 27 | 11 | 33 | 36 | 37 | 43 | 50 | 42 | ||||||||||||
Phase III Trials Projects | 19 | 11 | 35 | 27 | 23 | 22 | 27 | 25 | ||||||||||||
Life-cycle Management Projects | 34 | 46 | 56 | 69 | ||||||||||||||||
Blood Pressure Screenings (Africa) | 5.7 m | 9.97 m | 13.5 m | 16.7 m | ||||||||||||||||
New Phase I Projects | 5 | 3 | 4 | 3 | 1 | 1 | 1 | 5 | 5 | 3 | 3 | 5 | 5 | |||||||
New Phase II Projects | 2 | 3 | 4 | 12 | 1 | 4 | 5 | 5 | 1 | 4 | 3 | 8 | 8 | |||||||
New Pivotal Study Projects | 2 | 1 | 5 | 6 | 6 | 6 | 3 | 1 | 5 | 6 | 8 | 8 | ||||||||
New Projects to Registration | 3 | 1 | 3 | 1 | 5 | 5 | 1 | 3 | 2 | 2 | ||||||||||
NME Phase I (Oncology) | 21 | 19 | 18 | 17 | 26 | 26 | 21 | 21 | 20 | 18 | 18 | 20 | 19 | 20 | 21 | 21 | ||||
NME Phase II (Oncology) | 3 | 4 | 10 | 10 | 20 | 20 | 25 | 22 | 25 | 27 | 27 | 25 | 24 | 25 | 21 | 21 | ||||
NME in Late-stage Development (Oncology) | 5 | 4 | 4 | 4 | 11 | 11 | 14 | 17 | 14 | 12 | 12 | 7 | 9 | 10 | 10 | 10 | ||||
NME Phase I (Biopharmaceuticals) | 13 | 12 | 12 | 13 | 13 | 13 | 13 | 13 | 14 | 16 | 16 | 17 | 16 | 17 | 14 | 14 | ||||
NME Phase II (Biopharmaceuticals) | 18 | 17 | 17 | 17 | 23 | 23 | 22 | 22 | 21 | 22 | 22 | 20 | 21 | 21 | 21 | 21 | ||||
NME in Late-stage Development (Biopharmaceuticals) | 4 | 4 | 3 | 2 | 3 | 3 | 3 | 3 | 5 | 5 | 5 | 4 | 6 | 5 | 5 | 5 | ||||
Healthcare Workers Trained | 10.82 k | 35.89 k | 81.61 k | 132.25 k | ||||||||||||||||
People Reached (Healthcare Programmes) | 7.17 m | 12.01 m | 16.42 m | 25.03 m | ||||||||||||||||
People Reached (Patient Assistance Programmes) | 9 m | 9.3 m | 9.7 m | 10.1 m | ||||||||||||||||
NME Phase I | 34 | 26 | 32 | 27 | ||||||||||||||||
NME Phase II | 20 | 25 | 39 | 36 | ||||||||||||||||
NME in Late-stage Development | 11 | 8 | 8 | 10 | ||||||||||||||||
Countries | 100 | 100 | 100 | 100 | ||||||||||||||||
Health Facilities Activated | 827 | 2 k | 2.62 k | 3.36 k | ||||||||||||||||
Patients Included in Clinical Trials | 33 k | |||||||||||||||||||
Scientific Collaborations | 600 | 630 | 730 | 800 | ||||||||||||||||
Young Health Programme Members | 2.25 m | 3.01 m | 4.01 m |
FY, 2019 | FY, 2018 | FY, 2017 | |
---|---|---|---|
Male, percent | 10% | 10% | 10% |
Male (Senior and Middle Management), percent | 10.9% | 11.1% | 11.1% |
Female (Senior and Middle Management), percent | 9.1% | 8.9% | 8.9% |
Female (Management), percent | 8.3% | 8.3% | 8.1% |
Female (Executive Leadership), percent | 6.4% | 6% | 5.6% |
Male (Executive Leadership), percent | 13.6% | 14% | 14.4% |
Female (Board), percent | 6.7% | 8.4% | 8.4% |
Male (Board), percent | 13.3% | 11.6% | 11.6% |
Male (Management), percent | 11.7% | 11.7% | 11.9% |
Female, percent | 10% | 10% | 10% |